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Background: Studying DNA methylation changes in the context of structural rearrangements and point mutations
as well as gene expression changes enables the identification of genes that are important for disease onset and
progression in different subtypes of acute myeloid leukemia (AML) patients. The aim of this study was to identify
differentially methylated genes with potential impact on AML pathogenesis based on the correlation of methylation
and expression data.
Methods: The primary method of studying DNA methylation changes was targeted bisulfite sequencing capturing
approximately 84 megabases (Mb) of the genome in 14 diagnostic AML patients and a healthy donors’ CD34+
pool. Subsequently, selected DNA methylation changes were confirmed by 454 bisulfite pyrosequencing in a larger
cohort of samples. Furthermore, we addressed gene expression by microarray profiling and correlated methylation
of regions adjacent to transcription start sites with expression of corresponding genes.
Results: Here, we report a novel hypomethylation pattern, specific to CBFB-MYH11 fusion resulting from inv(16)
rearrangement that is associated with genes previously described as upregulated in inv(16) AML. We assume that
this hypomethylation and corresponding overexpresion occurs in the genes whose function is important in inv(16)
leukemogenesis. Further, by comparing all targeted methylation and microarray expression data, PBX3 differential
methylation was found to correlate with its gene expression. PBX3 has been recently shown to be a key interaction
partner of HOX genes during leukemogenesis and we revealed higher incidence of relapses in PBX3-overexpressing
patients.
Conclusions: We discovered new genomic regions with aberrant DNA methylation that are associated with
expression of genes involved in leukemogenesis. Our results demonstrate the potential of the targeted approach
for DNA methylation studies to reveal new regulatory regions.
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Changes in DNA methylation patterns are a known hall-
mark of acute myeloid leukemia (AML) and underlie AML
pathogenesis [1]. DNA methylation in patients with AML
has been studied extensively and may reflect either specific
molecular abnormalities or characterize a group of patients
without an apparent molecular aberration. Specific trans-
locations such as PML-RARA, AML1-ETO (RUNX1-
RUNX1T1), MLL translocations or CBFB-MYH11 fusion,
as well as CEBPA, NPM1, IDH1/IDH2, DNMT3A, TET2
and RUNX1 mutations have been described to display
distinct methylation signatures [2-4]. These epigenetic
profiles are usually accompanied by specific gene ex-
pression features. Studying genes that are epigenetically
deregulated in different groups of patients may contrib-
ute to a more detailed understanding of pathways in-
volved in the leukemic transformation. Importantly, the
effect of DNA methylation changes is greatly dependent
on the location of differentially methylated regions
(DMRs) [5]. New approaches using next-generation se-
quencing enable studying of DMRs scattered throughout
the genome and targeted bisulfite sequencing offers a rea-
sonably balanced ratio between cost and informativeness
(number of CpGs covered) [6]. The link between gene ex-
pression and DNA methylation data is needed to find
pathologically relevant DNA methylation changes, espe-
cially because many (or even the majority of) DMRs re-
flect the tissue of origin and not leukemia (cancer) specific
changes [7].
In this study, 84 megabases (Mb) of 14 AML genomes
and one CD34+ pool of cells from healthy donors were
captured for DNA methylation and gene expression
profiling. The aim was to identify differentially methyl-
ated genes with potential impact on AML pathogenesis
based on the correlation of methylation and expression
data.
AML patients with CBFB-MYH11 fusion (CBFB - Core-
binding factor, beta subunit; MYH11 - Myosin, heavy
chain 11) resulting from inv(16) rearrangement clustered
together in a hierarchal DNA methylation and expression
analysis. The majority of differentially methylated regions
unique for CBFB-MYH11 patients were hypomethylated
and genes assigned to such regions were previously de-
scribed as overexpressed in inv(16) AML [8].
PBX3 (pre-B-cell leukemia homeobox 3), recently
demonstrated as an important cofactor of HOXA9 in
leukemogenesis [9], was validated as a gene whose gene
expression levels correlated with DNA methylation of
its putative regulatory region across AML subtypes. The
importance of PBX3 is underlined by the fact that
PBX3-overexpressing patients relapse more frequently. In
summary, we discovered new genomic regions affected by
aberrant DNA methylation that are associated with expres-
sion of genes implicated in leukemogenesis.Results
Inv(16) methylation and expression cluster
We performed targeted bisulfite sequencing to discover
specific methylation changes in 14 AML samples of di-
verse clinical and genetic background versus a pool of
CD34+ healthy control cells (see Table 1 for patients’
characteristics). Agilent’s SureSelectXT Human Methyl-
Seq system was used to interrogate DNA methylation of
selected regions (84 megabases in total) of their ge-
nomes. These targeted regions comprise CpG islands,
CpG shores and shelves, as well as cancer and tissue-
specific DMRs. For all samples, on-target rates were
very good (about 95% for +/− 100 bp), while the per-
centage of targets above 20× coverage varied more
widely (between ~ 70% and 90%). Targeted methylation
data were correlated with previously obtained whole-
genome bisulfite (WGBS) data (unpublished) for 3
cross-experiment (WGBS/target enrichment) samples.
Taking into account positions with minimal coverage of
10, there was a strong positive correlation (R ≥ 0.97) in
all cases.
The hierarchal clustering analysis was done with the R
package Pvclust [10] using the correlation as a distance
measure and Ward’s method. Only positions of auto-
somes (i.e. excluding mitochondria and sex chromosome
calls) with coverage at least 10 and available for all sam-
ples (n = 2 010 310) were included in the analysis. From
the clinical and molecular characteristics, only CBFB-
MYH11 patients (samples 1 and 2) clustered together. In
Figure 1A, clustering of all CpGs is shown (for separate
clustering of CpGs inside or outside CpG islands see the
Additional file 1: Figure S1A and S1B). None of the other
molecular abnormalities formed clusters and we did not
observe any effect of clinical status of AML (de novo,
therapy-related, or AML with myelodysplasia-related
changes). One of the inv(16) sample was derived from
BM (sample 1) while the other (sample 2) from PB. Import-
antly, this had no effect on their clustering consistency.
We investigated this uniformity between the results from
BM and PB in more details using 454 pyrosequencing in a
larger number of patients (see below).
Clustering of gene expression data for 8 884 genes with
detection P value ≤ 0.05 in all 14 AML patients and 4
CD34+ healthy control cells confirmed the inv(16) cluster
(Figure 1B). Consistent with the DNA methylation data,
no other characteristics formed clusters. The selection of
these 14 AML patients was done randomly throughout
various clinical subgroups (de novo, secondary after MDS,
secondary after breast cancer, AML with dysplasia) with
the aim to find common DNA methylation changes
among diverse AML subtypes. Therefore, we cannot make
any general conclusions with regard to the existence/non-
existence of specific DNA methylation/gene expression
profiles other than those demontrated in inv(16) AML,
Table 1 Characteristics of AML patients
Sample ID Genetic aberration Clinical characterization FAB subtype Gender Material % blasts
AML_1 CBFB-MYH11, FLT3-ITD de novo AML AML M4 male BM 68
AML_2 CBFB-MYH11 de novo AML AML M4 female PB 40
AML_3 NPM1 therapy-related AML* AML M1 female PB 67
AML_4 MLL-PTD therapy-related AML* AML M4 female BM 42
AML_5 NPM1, DNMT3A, FLT3-ITD AML with multilineage dysplasia AML M2 female PB 58
AML_6 none AML with multilineage dysplasia AML M1 female BM 82
AML_7 NPM1, DNMT3A, FLT3-ITD de novo AML AML M4 male BM 94
AML_8 FLT3-ITD de novo AML AML M1 male BM 87
AML_9 FLT3-ITD de novo AML AML M1 male BM 89
AML_10 NPM1, FLT3-ITD de novo AML AML M2 female BM 75
AML_11 MLL-PTD de novo AML AML M1 male BM 92
AML_12 MLL-PTD, CEBPA de novo AML AML M1 female PB 80
AML_13 NPM1, CEBPA AML after MDS AML M6 male PB 60
AML_14 none AML after MDS AML M2 male PB 44
CD34+ pool of 4 CD34+ healthy control cells males
AML_1 to AML_14 are AML patients at diagnosis that were subjected to targeted bisulfite sequencing and gene expression profiling; CD34+ is a healthy control’s
pool; *after breast cancer; BM – bone marrow, PB – peripheral blood.
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(see below).
Hypomethylation signature of inv(16) AML patients
We extracted genomic regions being uniquely differen-
tially methylated in CBFB-MYH11 patients. There was a
clear tendency towards hypomethylation with 125 out of
182 regions (69%) displaying lower DNA methylation
levels compared to the healthy donors’ CD34+ pool of
cells. All CBFB-MYH11 DMRs were uploaded to GREAT
[11] and enrichment for genes previously described as up-
regulated in inv(16) AML patients was observed (reported
in ref. [8], ID: VALK_AML_CLUSTER_9; Additional file 2:
Table S1). This enrichment set comprised 10 genomic
regions assigned to 6 genes – MN1, SPARC, ST18, DHRS3,
FAM171A and BAHCC1 (see Additional file 3: Table S2).
MN1, SPARC, ST18, FAM171A and DHRS3 were chosen
for hypomethylation validation by 454 bisulfite pyrose-
quencing. As we were primarily interested in hypome-
thylation associated with overexpression, BAHCC1 was
excluded from the methylation/expression validation,
because its expression levels were undetectable in
AML as well as in healthy donors’ samples according
to microarray expression data. For MN1 and SPARC,
two regions per gene were studied.
In summary, altogether 21 inv(16) AML, 15 non-inv(16)
AML M4, 19 other AML (1 AML M0, 3 AML M1, 6
AML M2, 3 AML M3, 3 AML M5a, 2 AML M5b, 1
AML M6) and 10 healthy controls were examined. DNA
methylation of individual regions (corresponding to indi-
vidual amplicons) was expressed as an average DNAmethylation of all CpGs in that particular region. Average
levels of DNA methylation in assigned regulatory regions
of MN1, SPARC, ST18 and DHRS3 were significantly
lower for inv(16) versus non-inv(16) AML M4, other
AML subtypes and healthy controls (P < 0.0001) (see
Figure 2). Sequencing of FAM171A failed twice in all
samples probably due to the low complexity of the
amplicon (because of the long stretches of identical
bases – homopolymers) introduced after bisulfite con-
version and FAM171A was therefore excluded from
further analysis. For MN1, both of the studied regions
displayed lower levels of methylation (for MN1_re-
gion_2 hypomethylation graph see Additional file 4:
Figure S2A). For SPARC, the second studied region
(SPARC_region_2) had low DNA methylation levels in
inv(16) as well as in other AML and healthy donors
(see Additional file 4: Figure S2B). Therefore only methyla-
tion of region 1 has a potential impact on SPARC expression.
The 454-pyrosequencing results point to the site-specific
CBFB-MYH11 hypomethylation signature of genomic re-
gions assigned toMN1, SPARC, ST18 and DHRS3.
As we used either PB or BM as a starting material, we
investigated whether there is a concordance between
DNA methylation results from PB and BM in 10 AML
patients with both materials at diagnosis available. We
found high correlation between PB and BM results for
all of the studied regions (R = 0.96).
Further, we evaluated expression levels of MN1, SPARC,
ST18 and DHRS3 by TaqMan gene expression assays in all
samples already examined by 454 pyrosequencing. As can
be seen in Figure 3, inv(16) patients had higher average
Figure 1 Inv(16) methylation and expression cluster. (A)
Hierarchal DNA methylation clustering of CpGs (n = 2 010 310) using
the correlation as a distance measure and Ward’s method (AML_1 to
AML_14 – AML patients; CD34_pool – healthy control’s CD34+ pool)
indicating CBFB-MYH11 methylation cluster (in ellipse), other
molecular abnormalities did not form clusters neither clinical
characteristics did it; (B) Hierarchal gene expression clustering of
altogether 8884 genes with a detection P value≤ 0.05 in all 14 AML
patients (AML_1 to AML_14) and 4 CD34+ healthy control cells
confirmed inv(16) cluster (in ellipse).
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non-inv(16) AML samples, but only in ST18 when com-
pared to healthy donors.
Accordingly, ST18 was the most overexpressed gene in
inv(16) AML compared to CD34+ cells of healthy controls
in the microarray expression data. However, expression
for all 3 remaining genes – MN1, SPARC, and DHRS3 –
was also upregulated in inv(16) AML (approximately
3-times higher than in CD34+ cells of healthy controls).
Due to this inconsistency, we decided to re-measure
gene expression by the use of SybrGreen RQ-PCR. This
approach gave us results more similar to those ob-
served by Illumina expression microarrays. As seen in
Figure 4, differences in the gene expression levels be-
tween inv(16) AML and healthy controls increased sig-
nificantly for MN1 and SPARC. For DHRS3, the ratio of
expression between inv (16) and healthy donors chan-
ged only slightly, and for ST18 remained the same. One
possible explanation of this discrepancy is the genomic
location of primers. SybrGreen RQ-PCR primers for
MN1 and SPARC are located within the same exons as
are the probes on the Illumina expression microarray,
while TaqMan primers for MN1 and SPARC have
different, exon-exon locations. On the contrary, both
types of primers (TaqMan and SybrGreen) for ST18 and
DHRS3 have exon-exon locations. We checked Sybr-
Green RQ-PCR products specificity by melting analysis
in all samples and no unspecificity was detected.
It seems that in this particular case the selection of
PCR detection system may influence results in a
considerable manner. In general, this issue deserves fur-
ther exploration.
In summary, ST18 is the only overexpressed gene
in inv(16) compared to other AML subtypes and
healthy donors, irrespectively of the RQ-PCR system
used.
Correlation of methylation data with expression
For each transcription start site (TSS), a window was
defined from 5 kb up- to 1 kb downstream of that TSS.
Targeted regions overlapping this window were associ-
ated with the gene of the given TSS. GENCODE v14
gene annotation was used for assigning DNA methyla-
tion of target regions to corresponding genes. Expres-
sion and methylation data were then correlated using
Spearman rank tests. The small sample size did not allow
for filtering based on P values and thus an ad hoc measure
was employed, requiring strong anti-correlation (R ≤ −0.7),
and a change of methylation between control and at least
one AML sample 2-fold or greater (with either the control
or at least one of the AMLs having methylation ratio 0.3
or greater). These strict filtering parameters resulted in a
list of 163 genomic regions assigned to 130 unique genes
(see Additional file 5: Table S3). Among these genes, we
Figure 2 Hypomethylation signature in inv(16) AML. Hypomethylation of MN1 (A), SPARC (B), ST18 (C) and DHRS3 (D) regulatory regions in
inv(16) patients compared to AML M4 without inv(16), other AML subtypes and healthy controls; asterisks correspond to statistically significant
changes of expression in inv(16) patients versus other groups, ***P < 0.0001.
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DNA methylation and gene expression changes observed
in this cohort of 14 AML patients.
PBX3 and GFI1 differential methylation is involved in their
expression regulation
The DMRs associated with PBX3 are located down-
stream (−160 to −1451 bp) of annotated CpG island (for
exact location see Additional file 5: Table S3). We focused
on a DMR encompassing a TAF1 binding site (chr9:128
510 974–128 511 259 according to GRCh37/hg19). TAF1
encodes the largest subunit of TFIID and this subunit
binds to core promoter sequences encompassing TSSs.
We measured the expression of PBX3 mRNA in 123
AML diagnostic samples and 15 healthy controls (for a
graph see Additional file 6: Figure S3). 24% of AML had
down- and 22% upregulated PBX3 expression (with a
minimum change in the expression of more than 2-fold
and at the same time of more than one order of magni-
tude from healthy donors’ PBX3 average expression).
454 pyrosequencing established the role of DNA methy-
lation in down- and upregulation of PBX3 in 30 AML
patients at diagnosis (all of them with blast count ≥ 60%;
Figure 5). Elevated levels of PBX3 were connected withhypomethylation of a regulatory region (median methy-
lation level 0.25, range 0.15 – 0.36; P < 0.0001), whereas
decreased levels of expression with hypermethylation
(median methylation level 0.51, range 0.31 – 0.98; P =
0.002). Control samples of healthy donors and AML
samples with normal PBX3 expression displayed inter-
mediate levels of methylation (median 0.35, range 0.19 –
0.51). These results demonstrate the link between PBX3
expression and DNA methylation levels of the PBX3 regu-
latory region located downstream of the PBX3 annotated
CpG island.
Regarding GFI1, we examined a 409 bp long region
within the GFI1 promoter (chr1:92 952 229–92 952
637). Average DNA methylation levels of healthy con-
trols (n = 14) fluctuated around 3.86%. Very similar to
that, DNA methylation levels of AML within normal
gene expression range were 4.54%. Only a minority of
AML samples (3/64) showed decreased GFI1 expression
levels. However, all 3 GFI1-downregulated patients dis-
played higher methylation levels – 22.8%, 28.9% and
19%, respectively. On the contrary, upregulation of GFI1
was not connected with any significant changes of DNA
methylation levels, probably due to the fact that normal
DNA methylation levels were already low, therefore any
further decrease would not have a functional role.
Figure 3 Expression of hypomethylated genes in inv(16) AML measured by TaqMan gene expression assays. Relative expression value of
MN1 (A), SPARC (B), ST18 (C) and DHRS3 (D) in inv(16) AML patients versus other AML subtypes and healthy control cells; MNC – mononuclear
cells; asterisks correspond to statistically significant changes of expression, ***P < 0.0001, *P < 0.05, ns – not significant.
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AML patients
Because PBX3 is one of the four genes, whose common
expression signature was described as having an impact
on overall survival (OS) in AML patients [12], we de-
cided to evaluate its expression levels in terms of OS
and relapse-free survival (RFS). Only patients receiving
standard curative therapy and those who did not die
during the first induction were included in this analysis.
Altogether 40 AML patients were assessed, 21/40 had
low and 19/40 had high expression levels. Low and high
expression levels were defined as a change in expression
of at least one order of magnitude as well as 2-fold from
healthy donors’ average PBX3 expression.
We did not observe any effect of PBX3 expression levels
on OS in AML patients (Figure 6A), however we found
higher relapse rates in AML patients with overexpressed
PBX3 (Figure 6B, P = 0.004).
We also performed multivariate analysis for both OS
and RFS. Firstly, we tested the following parameters by
univariate analysis: age, white blood count (WBC),
complete remission after induction therapy (CR after
induction), good/intermediate/poor prognosis accord-
ing to cytogenetics, PBX3 expression and FLT3-ITDstatus. For OS, only CR after induction was statistically
significant in both univariate and multivariate analyses
(P < 0.001). For RFS, parameters significant in univari-
ate testing (WBC, CR after induction, FLT3-ITD status
and PBX3 expression) were evaluated by Cox regression.
Only CR after induction and PBX3 expression retained
statistical significance (P = 0.002 and P = 0.028, respect-
ively) in multivariate testing.
Furthermore, we evaluated whether there is an associ-
ation between PBX3 expression levels and presence of
MLL-PTD or belonging to prognostically adverse AML
subgroup. No such correlation was found, on the other
hand there was no PBX3-overexpressing patient among
AML patients within the prognostically favourable sub-
group (0/6 cases from prognostically favourable versus
26/46 cases from prognostically intermediate or adverse
subgroup overexpress PBX3, 0% versus 57% respectively,
P = 0.02). Leukemic transformation mediated by MLL-
fusion proteins has been suggested to be dependent on
the presence of PBX3 expression [9]. In our cohort, all
three MLL-translocated patients, two with MLLT3-MLL
(MLL-AF9) and one with MLL-MLLT1 (MLL-ENL), had
upregulated PBX3 expression, but the low number of MLL
translocations limited statistical testing of this association.
Figure 4 Expression of hypomethylated genes in inv(16) AML measured by SybrGreen RQ-PCR. Relative expression value of MN1 (A),
SPARC (B), ST18 (C) and DHRS3 (D) in inv(16) AML patients versus other AML subtypes and healthy control cells; MNC – mononuclear cells;
asterisks correspond to statistically significant changes of expression, ***P < 0.0001, *P < 0.05, **P < 0.01, ns – not significant.
Figure 5 PBX3 expression levels associated with DNA
methylation of its downstream located regulatory region. DNA
methylation levels in AML patients with upregulated (up),
downregulated (down) and normal levels of PBX3 expression
demonstrating the impact of PBX3 methylation on expression;
upregulation and downregulation was defined as a change in
expression of at least one order of magnitude as well as 2-fold
from healthy donors’ average PBX3 expression; asterisks
correspond to statistically significant changes of methylation,
***P < 0.0001, **P = 0.002.
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Here, we report a CBFB-MYH11, i.e. inv(16), specific hy-
pomethylation that may play a role in upregulation of
some previously described inv(16) overexpressed genes
[8]. We analysed DNA methylation and expression data of
MN1, SPARC, ST18 and DHRS3 in 55 AML patients and
10 healthy controls. Lower methylation levels of these
genes in inv(16) patients versus other AML and healthy
donors were confirmed. When measured by TaqMan gene
expression assays, inv(16)-specific overexpression of MN1,
SPARC, ST18 and DHRS3 was found with respect to non-
inv(16) AML, but only in ST18 in comparison with healthy
donors. This was inconsistent with the Illumina microarray
expression data as well as previously published data [8].
Therefore, we re-measured the results using SybrGreen
RQ-PCR and we obtained different values. In this RQ-
PCR experiment, changes in expression levels (between
inv(16) AML and healthy donors) were also significant for
MN1 and SPARC. We excluded both the role of PCR non-
specificity and DNA contamination. Interestingly, MN1
and SPARC primers for SybrGreen RQ-PCR, and MN1
and SPARC probes on the expression microarray, are lo-
calized within the same exons, while MN1 and SPARC
TaqMan probes have different, exon-exon localizations.
We cannot claim that this is the only reason for the
Figure 6 Impact of PBX3 expression levels on prognosis. (A)
Kaplan–Meier curves of overall survival (OS) in AML with low versus
high expression of PBX3 displaying no significant difference between
these two groups of AML patients; (B) Cumulative incidence of
relapse showing higher relapse rates in PBX3-overexpressing AML
patients (P = 0.004).
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examination in future studies. It is of interest that the
results obtained by SybrGreen RQ-PCR are in agree-
ment with the publicly available data (GSE34823) of
the study of Bletiere et al. [13].
Average gene expression levels of MN1, SPARC and
ST18 extracted from the above-mentioned dataset are
higher in inv(16) AML in comparison with healthy do-
nors’ bone marrow (4-times for MN1 and SPARC, 7-times
for ST18), and DHRS3 expression is basically the same in
both groups.
Further, we extracted the data from The Cancer Genome
Atlas (TCGA, https://tcga-data.nci.nih.gov/tcga/) and they
also confirmed a link between hypomethylation of MN1
and DHRS3 regulatory regions and their overexpression in
inv(16) AML when compared with AML samples with
normal karyotype (healthy controls data were not avail-
able). Regulatory regions corresponding to remaining
genes lacked information of their methylation status inTCGA due to the absence of appropriate CpGs in
HumanMethylation450 BeadChip used at TCGA study
[3]. This supports the profitability of studying DNA
methylation using targeted bisulfite sequencing, which
provides more complex coverage than microarray based
techniques.
The hypomethylation pattern that we discovered in
inv(16) AML patients is remarkable also with respect to
the very recently published data of Mandoli and col-
leagues [14]. For the first time, their study revealed the
involvement of CBFB-MYH11 not only in repression but
as well in transcriptional activation. The direct involve-
ment of CBFB-MYH11 in overexpression of MN1, ST18
and SPARC is supported with 2-fold downregulation of
these genes upon CBFB-MYH11 knockdown as reported
in their work. However, none of the 1874 high-confidence
CBFB-MYH11 binding sites [14] overlaps with any of the
hypomethylated regions reported here. DHRS3 was among
the genes upregulated upon CBFB-MYH11 knockdown,
which is in agreement with its disputable upregulation in
inv(16) AML. There were great differences in localization
of hypomethylated regions with respect to TSSs of indi-
vidual genes. With regard to MN1 and SPARC, the hypo-
methylation was located not far from their TSSs (for
location see Additional file 3: Table S2), which makes the
assumption of their role in the expression of these genes
more straightforward. Moreover, MN1 and SPARC poten-
tial regulatory regions overlap regions of active chromatin
(enhancers) in mobilized CD34+ cells as observed in the
EpiGenome Browser (http://epigenomegateway.wustl.edu/
browser) suggesting a role of these regions in transcription
regulation. On the contrary, differentially hypomethylated
sites assigned by GREAT to ST18 and DHRS3 are placed
much farther from their TSSs, specifically approximately
275 kilobases (kb) downstream for ST18 and 277 kb up-
stream for DHRS3. ST18 and DHRS3 assigned regulatory
regions are placed within chromatin marked with low
transcription activity and enhancer, respectively (in mobi-
lized CD34+ cells, data from EpiGenome Browser).
MN1 expression levels have been shown to stratify
prognosis of cytogenetically normal (CN) AML patients
and its overexpression is connected with a poor outcome
of CN-AML patients [15,16]. Nevertheless, inv(16) AML
patients are generally associated with a good prognosis
[17,18] in spite of their frequent MN1 overexpression.
Functional studies have proved that overexpression of
MN1 cooperates with inv(16) in developing AML in vivo
and that neither inv(16) or MN1 alone are capable of
promoting leukemia [19]. According to our results it
seems that hypomethylation is present uniquely in inv
(16) AML patients in both MN1 assigned regions (none
of the other AML subtypes or healthy controls displayed
MN1 hypomethylation in our cohort). So it supports the
theory that upregulation of some genes that might involve
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thylation may be therefore needed to ensure stable over-
expression of critical genes. Apparently the mechanism
of MN1 upregulation is different in non-inv(16) AML
patients or potentially hypomethylation of other regula-
tory areas located elsewhere may be involved.
Correlation between targeted DNA methylation and
microarray expression data of 14 AML patients and a
healthy controls’ CD34+ pool revealed PBX3 differential
methylation and gene expression. PBX3 (pre-B-cell
leukemia homeobox 3) is part of the three amino acid
loop extension (TALE) family of transcription factors,
which include the products of the Pbx and Meis genes
and are capable of heterodimerization with the Hox
proteins [20]. Recently, PBX3 was reported to have a
synergistic effect with HOXA9 in transforming normal
hematopoietic progenitor cells in vitro as well as in vivo
[8]. Moreover, PBX3 is one of the four genes (HOXA6,
HOXA9, PBX3 and MEIS1), whose common expression
signature was shown to influence overall survival in
CN-AML [12]. All evidence points to an important role
of PBX3 in leukemogenesis. This is the first report
uncovering DNA methylation as a plausible regulator of
PBX3 expression. We found a strong negative correl-
ation between levels of PBX3 methylation and expres-
sion in 8 healthy donors’ samples and 30 AML patients
at diagnosis (P < 0.0001 and P = 0.002 for upregulation
and downregulation, respectively). Localization of PBX3
differential methylation overlaps TAF1 binding site ac-
cording to ENCODE ChIP-Seq data from UCSC genome
browser. TAFs (TBP-associated factors) create a stable
complex with TBP (TATA-binding protein) and RNAPII
to form a preinitiation complex, so we may assume that
DNA methylation status of TAF1 binding site can directly
influence the accessibility of DNA for transcription en-
zymes. The probability of transcription initiation is pos-
sibly dependent on whether the DNA methylation is low
with high expression rates or DNA methylation is high
with decreased expression or finally intermediate DNA
methylation corresponding to in-between expression levels.
As PBX3 has a CpG island (CGI) overlapping its TSS, we
also looked at its methylation status. Based on targeted
methylation data, there was no methylation present either
in AML or healthy controls. Therefore, methylation status
of downstream located control element rather than CGI
methylation is most likely crucial for PBX3 expression.
Further we focused on potential prognostic significance of
PBX3 expression in terms of overall survival (OS) and in-
cidence of relapse. High PBX3 expression levels were not
related to different OS compared to AML patients with
low PBX3 expression, however relapse rates were signifi-
cantly higher in PBX3-overexpressing patients by both
univariate and multivariate testing. This suggests more
aggressive phenotype/course of disease of these patients,which is not reflected in the OS probably due to the early
and effective treatment of relapses – often followed by
bone marrow transplantation. We also showed that PBX3
overexpression did not occur in AML patients within cy-
togenetically favourable subgroup.
We validated the methylation/expression correlation
stated in the Additional file 5: Table S3 also for GFI1.
Moreover, the observed correlations are further sup-
ported by the presence of genes, for which the role of
DNA methylation is already published such as MPO
[21], CEBPα, DAPK1, IRF8 and PRDX8 [22,23].
Findings
We found a new hypomethylation signature specific for
inv(16) AML patients that may be responsible for over-
expression of some genes that are crucial for inv(16)
pathogenesis. MN1 gene is likely to be a key gene in-
volved in the pathogenesis of inv(16) AML and hypome-
thylation in the regulatory region near its TSS in inv(16)
AML patients was confirmed, even on the basis of publicly
available data from TCGA. Furthermore, we explored new
regulatory region for PBX3 and association of its methyla-
tion with PBX3 expression. Therefore, targeted bisulfite
sequencing represents a convenient approach in terms of
genome coverage and informativeness with a great poten-




For targeted bisulfite sequencing, 14 AML patients at
diagnosis (see Table 1) and pooled CD34+ cells from 4
healthy donors were sequenced. Genes selected based
on targeted bisulfite sequencing results were examined
using 454 bisulfite pyrosequencing in a larger cohort
of AML patients (their characteristics are given in
Additional file 7: Table S4). Informed consent was ob-
tained from all patients and healthy blood donors en-
rolled in the study. The study was approved by the
IHBT Institutional Ethics Committee according to the
Helsinki Declaration.
Sample preparation
Mononuclear cells (MNC) from peripheral blood (PB) or
bone marrow (BM) of the AML patients at diagnosis were
separated by Ficoll gradient centrifugation (Histopaque,
Sigma-Aldrich, Steinheim, Germany). CD34+ cells were
harvested from buffy coats of healthy blood donors
using MicroBead kits (Miltenyi Biotec GmbH, Bergish
Gladbach, Germany). The CD34+ pool was created by
mixing of 4 individual healthy blood donors’ separated
cells (all of them men aged 42 to 58 years old, median
age 45.5). DNA and RNA were extracted using AllPrep
DNA/RNA Mini Kit (Qiagen, Hilden, Germany). Bisulfite
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Bisulfite Kit (Qiagen) and eluted into 40 μl of EB buffer.
cDNA was prepared using M-MLV RT (Moloney Murine
Leukemia Virus Reverse Transcriptase, Promega, Madison,
WI, USA).
Targeted bisulfite sequencing
Preparation of targeted bisulfite libraries started with 3 μg
of genomic DNA and was carried out using SureSelectXT
Human Methyl-Seq kit (Agilent, Agilent Technologies, Santa
Clara, CA, USA) according to the manufacturer’s instruc-
tions. Libraries were multiplexed into 4 pools and each
pool was sequenced on 2 HiSeq™2000 (Illumina, San
Diego, CA, USA) lanes using 105 bp paired-end sequen-
cing reads with average coverage of 83 – ranging from
46 to 131.
454 bisulfite pyrosequencing
Bisulfite-treated (BS) DNA was subjected to 2-round
PCR. In the 1st round of PCR, loci-specific primers with
M13 universal tails were used to amplify regions of
interest. Subsequently, primers specific to M13 universal
tails now tailed with 454 -specific sequencing primers
and a unique barcode sequence (MID) were applied to
the 2nd PCR. Loci-specific primers were designed with
Methyl Primer Express v1.0 software (Applied Biosys-
tems Inc. Foster City, CA, USA; see Additional file 8:
Table S5 for primer sequences). HotStarTaq DNA poly-
merase (Qiagen) and manufacturer’s recommended PCR
reaction conditions were used for amplification. 2 μl of
BS DNA was added to the 1st PCR and 1 μl of 100× di-
luted 1st round PCR product was subjected to the 2nd
PCR. PCR cycling conditions were as follows: 1st round
PCR – initial denaturation (15 min at 95°C), followed by
35 cycles of denaturation (30s at 94°C), annealing (30s at
Ta °C, Ta – annealing temperature, see Additional file 8:
Table S5) and extension (1 min at 72°C), final extension
(10 min at 72°C); 2nd round of PCR - initial denaturation
(15 min at 95°C), followed by 26 cycles of denaturation
(30s at 94°C), annealing (30s at 60°C) and extension
(1 min at 72°C), final extension (5 min at 72°C). All
amplicons after 2nd round of PCR (up to 288 for one
run) were purified using Agencourt AMPureXP mag-
netic beads (Beckman Coulter, Fullerton, CA, USA)
and Biomek® FXP Laboratory Automation Workstation
(Beckman Coulter). Precise concentration of amplicons
were determined using Quant-iT™ PicoGreen dsDNA
Assay Kit (Life Technologies, Carlsbad, CA, USA) and
amplicons were equimolarly pooled to obtain amplicon
library with 109 fragments/μl concentration. Subsequent
procedures were carried out according to 454 amplicon
sequencing manuals (454 Life Sciences, Roche Applied
Science, Branford, CT, USA) on the GS Junior sequen-
cer (Roche). An average overall coverage of 225 readswas observed (ranging from 53 to 659 for individual
amplicons).
mRNA microarray profiling
Gene expression profiles from 14 AML patients and 4
CD34+ cells of healthy controls were generated by
HumanHT-12 v4 Expression BeadChip Kit (Illumina).
The chip scanning was done with a BeadStation 500 in-
strument (Illumina).
Quantitative real-time PCR (RQ-PCR)
The expression levels of selected genes were assessed
with TaqMan Gene Expression Assays (Life Technologies)
– see Additional file 9: Table S6 for individual Assay IDs.
GAPDH was utilized as a house-keeping gene. Amplifica-
tion was carried out with TaqMan Universal Master Mix
II (Life Technologies) and recommended cycling condi-
tions. SybrGreen RQ-PCR was performed using Quanti-
Tect SYBR Green PCR Kit (Qiagen) and pre-designed
KiCqStart® SYBR® Green primers (Sigma-Aldrich). Each
sample was run in duplicates on a StepOne instrument
(Life Technologies).
Molecular genetics
The presence of internal tandem duplication (ITD) in
the juxtamembrane (JM) and tyrosine kinase 1 (TKD1)
domains (exons 12–14) of FLT3 gene and the presence
of CBFB-MYH11 fusion transcript at diagnosis was de-
tected as described previously [24]. Further, we examined
mutations in NPM1 [25], CEBPA [26] and DNMT3A [27]
and intragenic MLL abnormalities such as partial tandem
duplications (MLL-PTD) by direct sequencing [28,29].
Cytogenetics
For cytogenetic analyses and fluorescence in situ
hybridization (FISH) the samples of bone marrow were
cultivated for 24 hrs in medium RPMI 1640 with 10%
of fetal calf serum. Twenty G-banded Wright-Giemsa
stained mitoses, if available, were evaluated. The karyotypes
were described following ISCN 2013 nomenclature. For
precise identification of chromosomal aberrations, FISH
with locus specific DNA probes (Vysis, Downers Grove,
IL, USA) and multicolor FISH with color kit probes and
ISIS computer analysis (both from Metasysteme, Altlusheim,
Germany) were used.
Data processing and statistics
Data from targeted bisulfite sequencing were processed
and evaluated using freely available programs: (i) FastQC
[30] (quality control of reads), (ii) Trimmomatic [31]
(removal of adapters/primer-dimers and bases with low-
quality scores), (iii) Bismark [32] (methylation-aware align-
ment of reads to the reference genome and computation of
methylation ratios). Differentially methylated target regions
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GREAT [11]. Quantile normalization and subtraction of
background was applied to the raw microarray expression
data in BeadStudio Data Analysis Software (Illumina). Raw
data from 454 pyrosequencing were processed using a fil-
ter template to relax the stringency of the original valley
filter (kindly provided by Dr. Esteban Czwan, Roche). This
step was necessary due to the lower complexity of bisulfite
treated DNA containing long stretches of homopolymers.
The filter template is available on-line (Additional file 10)
and its usage is described in Additional file 11. Data
from 454 pyrosequencing were aligned to a reference
in GS Amplicon Variant Analyzer (AVA) (Roche) software
and DNA methylation levels were assessed using the web-
based software BISMA [33].
Kaplan–Meier curves and two-sided log-rank test were
used to estimate the overall survival and to compare dif-
ferences between survival curves. The relations between
qualitative parameters were compared in contingency ta-
bles using Fisher’s exact test. For analyses of quantitative
data, medians were detected and non-parametric two-
tailed Mann–Whitney tests were performed. All these
tests were conducted at a level of significance of 0.05
using GraphPad Prism4 software (GraphPad Software,
San Diego, CA, USA). Cox regression analysis. was per-
formed applying the SPSS statistical software (SPSS Inc.,
Chicago, IL, USA).Additional files
Additional file 1: Figure S1. Inv(16) methylation clusters inside and
outside of CGIs. Hierarchal DNA methylation clustering of CpGs inside (A)
and outside (B) of CGIs using the correlation as a distance measure and
Ward’s method (AML_1 to AML_14 – AML patients; CD34_pool – healthy
control’s CD34+ pool) indicating CBFB-MYH11 methylation cluster
(in ellipse) consistently with clustering of all CpGs shown in Figure 1.
Additional file 2: Table S1. Enrichments for inv(16) uniquely
differentially methylated regions (DMRs) as observed in GREAT.
Enrichment terms observed after uploading of uniquely inv(16) DMRs to
on-line annotation tool GREAT [11].
Additional file 3: Table S2. Inv(16) enriched regions. Genomic regions
that were enriched for and associated with genes being previously
described as upregulated in inv(16) AML.
Additional file 4: Figure S2. Region_2 methylation levels of MN1 and
SPARC locus. (A) MN1_region 2 hypomethylation in inv(16) patients
compared to AML M4 without inv(16), other AML subtypes and healthy
controls; (B) SPARC_region 2 methylation levels are the same when
compared AML M4 without inv(16), other AML subtypes and healthy
controls.
Additional file 5: Table S3. Genes with strong negative correlation
between TSS adjacent DNA methylation levels and their expression.
Genes with strong anti-correlation (R ≤ −0.7) between DNA methylation
and expression, and with change of methylation between control and at
least one AML sample 2-fold or greater (with either the control or at least
one of the AMLs having methylation ratio 0.3 or greater); 163 genomic
regions assigned to 130 unique genes.
Additional file 6: Figure S3. Comparison of PBX3 expression levels.
PBX3 relative gene expression levels in AML patients at diagnosis versus
healthy controls’ samples.Additional file 7: Table S4. Samples used for inv(16) hypomethylation
validation. Characteristics of AML patients examined by 454 bisulfite
pyrosequencing to validate inv(16) hypomethylation of selected loci;
BM – bone marrow, PB – peripheral blood.
Additional file 8: Table S5. 454 bisulfite primers and annealing
temperatures Primer sequences and annealing temperatures used to
amplify regions of interest.
Additional file 9: Table S6. TaqMan gene expression assays IDs. IDs of
TaqMan probes used to measure gene expression of selected genes.
Additional file 10: Filter template. This template was used for 454 raw
sequencing data reprocessing as described in Additional file 10.
Additional file 11: 454 pyrosequencing – raw data acquisition.
Description of amplicon filter template usage that allowed to obtain
more reads from 454 bisulfite sequencing.
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